A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.

Trial Details

NCT ID
NCT04929223
Phase
PHASE1
Sponsor
Hoffmann-La Roche
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Inavolisib
  • Bevacizumab
  • Cetuximab
  • Atezolizumab
  • Tiragolumab
  • SY-5609
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Duarte, California, United States|34.13945,-117.97729
  • Encinitas, California, United States|33.03699,-117.29198
  • Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

  • Signed cohort-specific Informed Consent Form
  • Age \>= 18 years at time of signing Informed Consent Form
  • Biomarker eligibility as determined by:
  • A validated test approved by local health authorities for detection of the specified biomarkers/mutations.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →